Maekawa H
ORCID: 0000-0002-0200-414X
· 1 paper in corpus
The combination therapy of lenvatinib plus pembrolizumab (LP) is increasingly recognized as an important second-line regimen for advanced or recurrent endometrial cancer (EC). However, the safety and efficacy of conversion surgery with low …